Literature DB >> 20165825

[Human papillomavirus-associated warts in organ transplant recipients. Incidence, risk factors, management].

D Krüger-Corcoran1, E Stockfleth, J S Jürgensen, A Maltusch, I Nindl, W Sterry, B Lange-Asschenfeldt, C Ulrich.   

Abstract

Human papillomaviruses infect the squamous epithelia of the skin and cause warts, and are occasionally found in squamous cell carcinomas. Since cell-mediated immunity plays a crucial role in the control of HPV-infections, organ transplant recipients, unable to mount an adequate T-helper 1 cell-mediated immune surveillance, frequently develop widespread and resistant induced warts. Skin tumors, especially squamous cell carcinomas, are the most common post-transplantation neoplasm. Warts, actinic keratoses and invasive squamous cell carcinomas are known to develop at the same time in the areas. The role of HPV in the development of invasive squamous cell carcinoma under immunosuppression, remains to be elucidated in respect to common risk factors and increased numbers of warts potentially identifying patients at increased risk for carcinoma. We prospectively studied 1690 organ transplant recipients in the dermatology clinic at the Charité University Hospital in Berlin, to evaluate risk factors being involved in the development of HPV-induced warts and to assess a potential association of with the development of non-melanoma skin cancers in this population. The cumulative incidence of warts steadily increased throughout the post-transplant years. The presence of more than 10 verrucae was associated with the development of actinic keratoses, invasive squamous cell carcinoma and basal cell carcinoma. This study shows clear evidence that certain risk factors of skin carcinogenesis in organ transplant recipient such as increased age at transplantation, a high dose of immunosuppression related to a specific type of graft and use of azathioprine or cyclosporine are strongly associated with an increased incidence of warts. Furthermore, HPV-induced verrucae vulgares could be used as a potential predictor for the development of coincidental non melanoma skin cancer in organ transplant recipients and therefore could serve as an early identification marker of skin cancer high-risk patients. The challenging management of warts in organ transplantation patients is reviewed.

Entities:  

Mesh:

Year:  2010        PMID: 20165825     DOI: 10.1007/s00105-009-1860-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  39 in total

Review 1.  EXPERIMENTAL AND CLINICAL USE OF FLUORINATED PYRIMIDINES IN CANCER CHEMOTHERAPY.

Authors:  C HEIDELBERGER; F J ANSFIELD
Journal:  Cancer Res       Date:  1963-09       Impact factor: 12.701

2.  Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals.

Authors:  C A Harwood; C M Perrett; V L Brown; I M Leigh; J M McGregor; C M Proby
Journal:  Br J Dermatol       Date:  2005-01       Impact factor: 9.302

3.  Conversion to sirolimus: a useful strategy for recalcitrant cutaneous viral warts in liver transplant recipient.

Authors:  Sébastien Dharancy; Benoît Catteau; Laurent Mortier; Emmanuel Boleslawski; Nicole Declerck; Valérie Canva; Frédéric Piette; Philippe Mathurin; François René Pruvot
Journal:  Liver Transpl       Date:  2006-12       Impact factor: 5.799

4.  Common warts from immunocompetent patients show the same distribution of human papillomavirus types as common warts from immunocompromised patients.

Authors:  A Rübben; R Krones; B Schwetschenau; E I Grussendorf-Conen
Journal:  Br J Dermatol       Date:  1993-03       Impact factor: 9.302

5.  [Risk factors for cutaneous wart onset in transplant recipients].

Authors:  C Pruvost; D Penso-Assathiany; N Bachot; P Lang; J C Roujeau
Journal:  Ann Dermatol Venereol       Date:  2002-03       Impact factor: 0.777

6.  Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients.

Authors:  Hugo Bonatti; Felix Aigner; Eric De Clercq; Claudia Boesmueller; Andreas Widschwendner; Clara Larcher; Raimund Margreiter; Stefan Schneeberger
Journal:  Transpl Int       Date:  2007-03       Impact factor: 3.782

7.  Use of acitretin for the skin complications in renal transplant recipients.

Authors:  Z F Yuan; A Davis; K Macdonald; R R Bailey
Journal:  N Z Med J       Date:  1995-06-28

8.  Polyphenon E: a new treatment for external anogenital warts.

Authors:  S Tatti; E Stockfleth; K R Beutner; H Tawfik; U Elsasser; P Weyrauch; A Mescheder
Journal:  Br J Dermatol       Date:  2009-07-27       Impact factor: 9.302

9.  Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment.

Authors:  E Stockfleth; C Ulrich; T Meyer; E Christophers
Journal:  Recent Results Cancer Res       Date:  2002

10.  Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy.

Authors:  Jan N Bouwes Bavinck; Sylvie Euvrard; Luigi Naldi; Ingo Nindl; Charlotte M Proby; Rachel Neale; Damiano Abeni; Gian P Tessari; Mariet C W Feltkamp; Alain Claudy; Eggert Stockfleth; Catherine A Harwood
Journal:  J Invest Dermatol       Date:  2007-03-22       Impact factor: 8.551

View more
  5 in total

1.  [Precancerous tumors and carcinomas in situ of the skin].

Authors:  D Krüger-Corcoran; S Vandersee; E Stockfleth
Journal:  Internist (Berl)       Date:  2013-06       Impact factor: 0.743

2.  Prevention of infection caused by immunosuppressive drugs in gastroenterology.

Authors:  Katarzyna Orlicka; Eleanor Barnes; Emma L Culver
Journal:  Ther Adv Chronic Dis       Date:  2013-07       Impact factor: 5.091

Review 3.  Skin changes following organ transplantation: an interdisciplinary challenge.

Authors:  Claas Ulrich; Renate Arnold; Ulrich Frei; Roland Hetzer; Peter Neuhaus; Eggert Stockfleth
Journal:  Dtsch Arztebl Int       Date:  2014-03-14       Impact factor: 5.594

4.  Dermatological conditions seen in renal transplant recipients in a Singapore tertiary hospital.

Authors:  Choon Chiat Oh; Haur Yueh Lee; Bien Keem Tan; Pryseley Nkouibert Assam; Terence Yi Shern Kee; Shiu Ming Pang
Journal:  Singapore Med J       Date:  2018-10       Impact factor: 1.858

Review 5.  Immunosuppressive agents for dermatological indications in the ongoing COVID-19 pandemic: Rationalizing use and clinical applicability.

Authors:  Ananta Khurana; Snigdha Saxena
Journal:  Dermatol Ther       Date:  2020-06-23       Impact factor: 3.858

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.